Inhibrx Biosciences, Inc. 2025 Annual Report: Key Insights for Investors

Summary of Key Highlights

• Company Name Change & Corporate Structure: Inhibrx Biosciences, Inc. (formerly Ibex SpinCo, Inc.) completed its renaming on January 25, 2024, and is now operating as an independent entity headquartered in La Jolla, California.
• Stock Information: Common stock, par value \$0.0001, trading under the symbol INBX on The Nasdaq Global Market.
• Shares Outstanding & Public Float: As of March 11, 2026, there were 14,607,036 shares outstanding. As of June 30, 2025, public float was approximately \$174.6 million, based on a closing price of \$14.27 per share.
• Filing Status: The company is currently classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company.
• Forward-Looking Statements: The report contains numerous forward-looking statements regarding the progress of research and development, regulatory milestones, commercialization plans, and financial outlook.

Business Overview & Strategy

Inhibrx Biosciences, Inc. positions itself as a data-driven, innovative biotechnology company focused on the discovery and development of highly differentiated therapeutic candidates. The company emphasizes its ability to identify promising preclinical candidates efficiently and select the most impactful programs for clinical advancement.

Pipeline Maximization

• The company is committed to maximizing the potential of its therapeutic pipeline, seeking operational efficiency and capital effectiveness to deliver the greatest value to shareholders and the largest impact on patients.
• Strategic partnerships are being pursued to leverage expertise and resources that can accelerate product development and commercialization.

Research & Development Focus

• Inhibrx’s R&D programs are focused on advancing novel therapeutics through preclinical and clinical stages, with an emphasis on interpreting clinical trial data, including disease control and response rates.
• The company is actively working on manufacturing capabilities to support both clinical trials and eventual commercial use, should candidates receive regulatory approval.

Regulatory and Legal Environment

• The company highlights the complexities of the regulatory process, including the need for FDA and other agency approvals, ongoing compliance, and the risk of regulatory actions that could affect product commercialization or require corrective measures.
• Coverage, pricing, and reimbursement by third-party payors (including government and private insurers) are identified as significant factors for future sales and profitability of approved products.
• Ongoing compliance with environmental, health, and safety regulations is required, with references to the Clean Air Act, Clean Water Act, and other legislation.

Intellectual Property Strategy

• Inhibrx pursues robust patent protection strategies, aiming to secure patent term extensions where possible. However, there is no guarantee of success in all jurisdictions.
• The company also relies on trade secrets and confidentiality agreements with employees, consultants, and service providers to safeguard proprietary technology and inventions.

Human Capital and Corporate Governance

• As of December 31, 2025, Inhibrx employed 110 personnel (109 full-time), with a majority engaged in R&D and over 50 holding advanced degrees.
• The company underscores its commitment to diversity, innovation, and ethical conduct, including mandatory training on public company policies, anti-harassment, and whistleblower protections.
• Compensation includes competitive salaries, stock-based awards to align employee and shareholder interests, bonus plans, and retirement savings options.

Risk Factors and Forward-Looking Statements

• A comprehensive section cautions investors about risks related to clinical development, regulatory approvals, commercialization, market acceptance, competition, capital needs, and dependence on third-party partners.
• All forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from projections. The company does not undertake to update these statements except as required by law.

Shareholder and Market-Sensitive Information

• Potential Price-Sensitive Issues:
  • Any progress, delay, or results from clinical trials could significantly impact the share price.
  • Regulatory approvals (or setbacks) for key therapeutic candidates may move the market.
  • New strategic partnerships, patent grants, or enforcement actions could materially affect valuation.
  • Changes to reimbursement rates or payer coverage can affect future revenues.
  • Any indication of capital raises or financing requirements may be price sensitive.
• There are no explicit disclosures of imminent product launches, regulatory submissions, or unexpected events in this section of the report; however, the ongoing advancement of the pipeline and regulatory activities remain core potential value drivers for shareholders.

Access to Company Information

Inhibrx makes its SEC filings, including annual, quarterly, and current reports, freely available through its website and the SEC’s EDGAR system.

Disclaimer: This summary is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Investors should read the full SEC filings and consult their financial advisors before making investment decisions.

View Inhibrx Biosciences, Inc. Historical chart here